SG49772A1 - Thrombin receptor antagonists - Google Patents

Thrombin receptor antagonists

Info

Publication number
SG49772A1
SG49772A1 SG1996005407A SG1996005407A SG49772A1 SG 49772 A1 SG49772 A1 SG 49772A1 SG 1996005407 A SG1996005407 A SG 1996005407A SG 1996005407 A SG1996005407 A SG 1996005407A SG 49772 A1 SG49772 A1 SG 49772A1
Authority
SG
Singapore
Prior art keywords
thrombin receptor
receptor antagonists
hydrophobic radical
linkages
formula
Prior art date
Application number
SG1996005407A
Other languages
English (en)
Inventor
Robert M Scarborough
Original Assignee
Cor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cor Therapeutics Inc filed Critical Cor Therapeutics Inc
Publication of SG49772A1 publication Critical patent/SG49772A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
SG1996005407A 1992-07-30 1993-07-08 Thrombin receptor antagonists SG49772A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92234092A 1992-07-30 1992-07-30
US8078893A 1993-06-28 1993-06-28

Publications (1)

Publication Number Publication Date
SG49772A1 true SG49772A1 (en) 1998-06-15

Family

ID=26763931

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996005407A SG49772A1 (en) 1992-07-30 1993-07-08 Thrombin receptor antagonists

Country Status (10)

Country Link
US (1) US5866681A (de)
EP (1) EP0656008B1 (de)
JP (1) JP2675438B2 (de)
AT (1) ATE190625T1 (de)
AU (1) AU669922B2 (de)
CA (1) CA2140543C (de)
DE (1) DE69328104T2 (de)
IL (1) IL106197A (de)
SG (1) SG49772A1 (de)
WO (1) WO1994003479A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
JP3449620B2 (ja) * 1997-11-25 2003-09-22 シェーリング コーポレイション トロンビンレセプターアンタゴニスト
WO1999042475A1 (en) * 1998-02-19 1999-08-26 Ortho-Mcneil Pharmaceutical, Inc. Azole peptidomimetics as thrombin receptor antagonists
US6017890A (en) * 1998-02-19 2000-01-25 Ortho-Mcneil Pharmaceutical, Inc. Azole peptidomimetics as thrombin receptor antagonists
US6544982B1 (en) 1999-10-29 2003-04-08 Merck & Co., Inc. Thrombin receptor antagonists
US6403612B2 (en) 2000-01-31 2002-06-11 Merck & Co., Inc. Thrombin receptor antagonists
US6515023B2 (en) 2000-01-31 2003-02-04 Merck & Co., Inc. Thrombin receptor antagonists
IL153308A0 (en) 2000-06-15 2003-07-06 Schering Corp Thrombin receptor antagonists
US7235567B2 (en) 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
CA2432369A1 (en) 2000-12-20 2002-08-08 Bristol-Myers Squibb Pharma Company Cyclic derivatives as modulators of chemokine receptor activity
AR035720A1 (es) 2000-12-20 2004-07-07 Bristol Myers Squibb Pharma Co Derivados de amida ,composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de quimioquinas
US20040096443A1 (en) * 2002-03-08 2004-05-20 Traynelis Stephen Francis Treatment of neurodegenerative diseases and conditions using par1 antagonists
IL160918A0 (en) 2001-10-18 2004-08-31 Schering Corp Himbacine analogues as thrombin receptor antagonists
IL164376A0 (en) * 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
KR101026929B1 (ko) 2002-04-16 2011-04-04 쉐링 코포레이션 트리사이클릭 트롬빈 수용체 길항제
US7074765B2 (en) 2003-05-01 2006-07-11 The Regents Of The University Of Michigan Synthetic peptide analogs of Arg-Pro-Pro-Gly-Phe as selective inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4
ATE406366T1 (de) * 2004-05-28 2008-09-15 Schering Corp Gehinderte himbacinanaloga als thrombinrezeptorantagonisten
US7488752B2 (en) 2004-10-08 2009-02-10 Schering Corporation Thrombin receptor antagonists
WO2006105217A2 (en) 2005-03-31 2006-10-05 Schering Corporation Spirocyclic thrombin receptor antagonists
EP1999111B1 (de) 2006-03-29 2013-12-18 Merck Sharp & Dohme Corp. Monozyklische und bizyklische himbacin-derivate als thrombin-rezeptor-antagonisten
EP2266976B1 (de) 2006-04-13 2013-07-31 Merck Sharp & Dohme Corp. Fusionierte Ring-Thrombinrezeptorantagonisten
AU2007269830A1 (en) 2006-06-29 2008-01-10 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
AU2007305269A1 (en) 2006-10-04 2008-04-10 Schering Corporation Bicyclic and tricyclic derivatives as thrombin receptor antagonists
CA2681597A1 (en) * 2007-03-23 2008-10-02 Schering Corporation Reduction of adverse events after percutaneous intervention by use of a thrombin receptor antagonist
US20090022729A1 (en) * 2007-04-13 2009-01-22 Nigel Mackman Methods and compositions for treating cardiac dysfunctions
CL2009001214A1 (es) 2008-05-19 2010-12-31 Schering Corp Compuestos derivados de heterociclo, moduladores de serina proteasas composicion fa<rmacaeutica que los comprende; y su uso en el tratamiento de trastornos tromboembolicos
WO2011017296A1 (en) 2009-08-04 2011-02-10 Schering Corporation 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
EP2335717A1 (de) * 2009-11-16 2011-06-22 Institut National De La Recherche Agronomique PAR-1-Antagonisten zur Verwendung bei der Behandlung oder Prävention von Influenzavirus-Typ-A-Infektionen
EP2822557B1 (de) 2012-03-06 2017-08-23 Merck Sharp & Dohme Corp. Herstellung und verwendung bicyclischer himbacinderivate als par-rezeptor-antagonisten
WO2015026693A1 (en) 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives
EP3035928B1 (de) 2013-08-22 2023-10-18 Merck Sharp & Dohme LLC 3 -pyridyl-substituierte 6,6-difluor-bicyclische himbacinderivate
US20160200715A1 (en) 2013-08-22 2016-07-14 Merck Sharp & Dohme Corp. Preparation and use of 7a-heterocycle substituted- 6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
US9969724B2 (en) 2014-04-16 2018-05-15 Merck Sharp & Dohme Corp. Factor IXa inhibitors
CN116133660A (zh) 2020-07-22 2023-05-16 詹森药业有限公司 可用作因子XIa抑制剂的化合物
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2589720A1 (fr) * 1985-11-14 1987-05-15 Aubaniac Jean Ensemble prothetique pour l'articulation du genou
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5352664A (en) * 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
AU618029B2 (en) * 1987-11-02 1991-12-12 Imperial Chemical Industries Plc Polypeptide compounds
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5256766A (en) * 1991-02-19 1993-10-26 The Regents Of The University Of California Recombinant thrombin receptor and related pharmaceuticals
US5688768A (en) * 1991-02-19 1997-11-18 Cor Therapeutics, Inc. Recombinant thrombin receptor and related pharmaceuticals
JPH07507995A (ja) * 1992-03-02 1995-09-07 バイオジェン，インコーポレイテッド トロンビンレセプターアンタゴニスト

Also Published As

Publication number Publication date
IL106197A (en) 1999-11-30
WO1994003479A1 (en) 1994-02-17
AU669922B2 (en) 1996-06-27
EP0656008B1 (de) 2000-03-15
JPH07506115A (ja) 1995-07-06
JP2675438B2 (ja) 1997-11-12
US5866681A (en) 1999-02-02
DE69328104T2 (de) 2000-12-21
AU4668593A (en) 1994-03-03
EP0656008A1 (de) 1995-06-07
DE69328104D1 (de) 2000-04-20
IL106197A0 (en) 1994-05-30
CA2140543C (en) 2001-04-10
ATE190625T1 (de) 2000-04-15
CA2140543A1 (en) 1994-02-17

Similar Documents

Publication Publication Date Title
IL106197A0 (en) Thrombin receptor antagonists
DE3378052D1 (en) Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives
ECSP930999A (es) Nuevos compuestos utilizables como agentes edulcorantes, su procedimiento de preparacion
AP9801312A0 (en) 4-aminopyrrole (3,2-d) pyrimidines as neuropeptide y receptor anatagonist.
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
ES2000216A6 (es) Procedimiento para preparar un polipeptido purificado que tiene propiedades inhibidoras de la coagulacion de la sangre.
WO2000059497A8 (en) Pyrrolidine modulators of chemokine receptor activity
DE69904736D1 (de) Dithiocarbamyl-derivate geeignet als schmiermitteladditive
HU9501754D0 (en) Dolostatin analog
DK0773956T3 (da) Renset form for streptograminer, fremstilling deraf og farmaceutiske sammensætninger, der indeholder denne
ATE216375T1 (de) Aminothiazole derivate, ihre herstellung und sie enthaltenden pharmazeutischen zusammensetzungen
DE69425804D1 (en) Phosphonsäurediesterderivate
NZ336793A (en) Method for stabilizing peptides by adding an organic acid and then lyophilizing the peptide mixture
GR3029428T3 (en) Novel bisoxadiazolidine derivative
AU1721883A (en) Muramyl peptides
HUT73759A (en) Herbicidal substituted 1-phenyl or 1-pyridinyl benzotriazoles
ATE30429T1 (de) Acylamino-oxo- oder hydroxy-substituiertealkylamino thiazine und thiazepine.
ES2104174T3 (es) Derivados de bencilamino, bencilamido y bencilimido ciclicos utilizados como agentes antipsicoticos.
AU640236B2 (en) 3,7-diazabicyclo(3,3,1)nonane compounds useful as diuretics
MX9500228A (es) N-oxidos de 4-arilpiperazinas y 4-arilpiperidinas.
IE861361L (en) Bicyclic amino acid derivatives.
JPS6485998A (en) Acylated splenopentine, manufacture and use
IL94979A0 (en) Antiherpes pentapeptides and their preparation
ES557263A1 (es) Procedimiento para la obtencion de alanincompuestos n-sustituidos
PL312966A1 (en) Derivatives of thiocarbamoil